

2023

Step Therapy Criteria

Last Updated: 05/16/2023

HPMS Approved Formulary File Submission 00023576 Version Number 14

Biophosphates

Products Affected

- *risedronate sodium tablet 35 mg oral*

Details

Criteria	Trial of Alendronate
-----------------	----------------------

GLP-1 Agonists

Products Affected

- BYDUREON BCISE AUTO-INJECTOR SUBCUTANEOUS
2 MG/0.85ML SUBCUTANEOUS
- BYETTA 5 MCG PEN SOLUTION
PEN-INJECTOR 5 MCG/0.02ML
SUBCUTANEOUS
- BYETTA 10 MCG PEN SOLUTION
PEN-INJECTOR 10 MCG/0.04ML

Details

Criteria	Trial of Metformin
----------	--------------------

ICS/LABA/LAMA

Products Affected

- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT INHALATION
- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 200-62.5-25 MCG/ACT INHALATION

Details

Criteria	Trial of a LABA or LAMA containing product
-----------------	--

Topical PDE-4 Inhibitors

Products Affected

- EUCRISA OINTMENT 2 %
EXTERNAL

Details

Criteria	Trial of topical corticosteroid
-----------------	---------------------------------

Index

BYDUREON BCISE AUTO-
INJECTOR 2 MG/0.85ML
SUBCUTANEOUS.....2

BYETTA 10 MCG PEN SOLUTION
PEN-INJECTOR 10 MCG/0.04ML
SUBCUTANEOUS.....2

BYETTA 5 MCG PEN SOLUTION
PEN-INJECTOR 5 MCG/0.02ML
SUBCUTANEOUS.....2

EUCRISA OINTMENT 2 %
EXTERNAL4

risedronate sodium tablet 35 mg oral.....1

TRELEGY ELLIPTA AEROSOL
POWDER BREATH ACTIVATED
100-62.5-25 MCG/ACT INHALATION ...3

TRELEGY ELLIPTA AEROSOL
POWDER BREATH ACTIVATED
200-62.5-25 MCG/ACT INHALATION ...3